Latest Insider Transactions at Entasis Therapeutics Holdings Inc. (ETTX)
This section provides a real-time view of insider transactions for Entasis Therapeutics Holdings Inc. (ETTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Entasis Therapeutics Holdings Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Entasis Therapeutics Holdings Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 19
2021
|
Ruben Tommasi Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,759
-5.22%
|
$11,277
$3.19 P/Share
|
|
Oct 19
2021
|
Ruben Tommasi Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+25.77%
|
-
|
|
Oct 19
2021
|
Michael Gutch Officer |
SELL
Open market or private sale
|
Direct |
3,759
-7.52%
|
$11,277
$3.19 P/Share
|
|
Oct 19
2021
|
Michael Gutch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+33.33%
|
-
|
|
Oct 19
2021
|
John Patrick Mueller Chief Development Officer |
SELL
Open market or private sale
|
Direct |
4,001
-8.0%
|
$12,003
$3.19 P/Share
|
|
Oct 19
2021
|
John Patrick Mueller Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+33.33%
|
-
|
|
Oct 19
2021
|
Manoussos Perros President and CEO |
SELL
Open market or private sale
|
Direct |
11,974
-7.51%
|
$35,922
$3.19 P/Share
|
|
Oct 19
2021
|
Manoussos Perros President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
79,750
+33.33%
|
-
|
|
Jun 11
2021
|
Innoviva, Inc. |
BUY
Open market or private purchase
|
Indirect |
6,268,975
+38.53%
|
$12,537,950
$2.0 P/Share
|
|
May 03
2021
|
Innoviva, Inc. |
BUY
Open market or private purchase
|
Indirect |
3,731,025
+50.0%
|
$7,462,050
$2.0 P/Share
|
|
Apr 01
2021
|
David C Hastings Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+50.0%
|
-
|
|
Apr 01
2021
|
David D. Meek Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+50.0%
|
-
|
|
Apr 01
2021
|
Heather A. Berger Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+50.0%
|
-
|
|
Apr 01
2021
|
Howard Mayer Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+50.0%
|
-
|
|
Jan 15
2021
|
John Patrick Mueller Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Jan 15
2021
|
David Altarac Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Jan 15
2021
|
Elizabeth M Keiley General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Jan 15
2021
|
Manoussos Perros President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
79,750
+50.0%
|
-
|
|
Jan 15
2021
|
Matthew Ronsheim Chief of Pharma Sciences & MFG |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Jan 15
2021
|
Michael Gutch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Jan 15
2021
|
Ruben Tommasi Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+34.71%
|
-
|
|
Sep 28
2018
|
Astrazeneca PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
246,666
+10.23%
|
$3,699,990
$15.0 P/Share
|
|
Sep 28
2018
|
Astrazeneca PLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,918,185
+50.0%
|
-
|
|
Sep 28
2018
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,089,835
+33.31%
|
$16,347,525
$15.0 P/Share
|
|
Sep 28
2018
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,092,008
+50.0%
|
-
|